Dalazatide

Drug Profile

Dalazatide

Alternative Names: Debio-0824; ShK-186

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Airmid; University of California at Irvine
  • Developer Kineta; KPI Therapeutics; Seattle Childrens Research Institute; University of California at Irvine; University of Groningen
  • Class Amides; Peptides; Proteins
  • Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis; Psoriatic arthritis
  • Preclinical Inclusion body myositis; Lupus nephritis; Vasculitis
  • Research Inflammatory bowel diseases; Multiple sclerosis
  • No development reported Autoimmune disorders; Obesity

Most Recent Events

  • 22 May 2017 Preclinical trials in Inclusion body myositis in USA (SC), before May 2017
  • 22 May 2017 KPI Therapeutics plans proof of concept trials for Inclusion body myositis in USA, in 2017 (KPI Therapeutics website, July 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Netherlands (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top